About: Dysregulation of the immune response affects the outcome of critical COVID‐19 patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Dysregulation of the immune response affects the outcome of critical COVID‐19 patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Dysregulation of the immune response affects the outcome of critical COVID‐19 patients
Creator	Xu, Bin De-Xi, † Wang, Wen-Jing Wei, Lin-Lin Wei, Linlin
Source	Medline; PMC
abstract	OBJECTIVES: Critical cases of coronavirus disease 2019 (COVID‐19) are associated with a high risk of mortality. It remains unclear why patients with the same critical condition have different outcomes. We aimed to explore relevant factors that may affect the prognosis of critical COVID‐19 patients. METHODS: Six critical COVID‐19 inpatients were included in our study. The 6 patients were divided into two groups based on whether they had a good or poor prognosis. We collected peripheral blood samples at admission and the time point of exacerbation to compare differences in the phenotypes and functions of major populations of immune cells between the groups. RESULTS: On admission, compared to patients with poor prognoses, those with good prognoses had significantly higher counts of monocytes (p < 0.05), macrophages (p < 0.05), higher frequency of CD3(+)CD4(+)CD45RO(+)CXCR3(+) subsets (p < 0.05), higher frequency of CD14(+)CD11C(+)HLA‐DR(+) subset of dendritic cells (DCs) (p < 0.05), and a lower count of neutrophils (p < 0.05). At the time point of exacerbation, the proportions of naïve CD4(+) T cells (p < 0.05), Tregs, and Th2 cells in the poor prognosis group were relatively higher than those in the good prognosis group, and CD4(+) memory T cells were relatively lower (p < 0.05). CONCLUSION: According to our results, the poor prognosis group showed a worse immune response than the good prognosis group at the time of admission and at exacerbation. Dysregulation of the immune response affects the outcome of critical COVID‐19 patients. This article is protected by copyright. All rights reserved.
has issue date	2020-06-16(xsd:dateTime)
bibo:doi	10.1002/jmv.26181
bibo:pmid	32543740
has license	no-cc
sha1sum (hex)	93029948341507916e5ca60e5b0e21858b3578bc
schema:url	https://doi.org/10.1002/jmv.26181
resource representing a document's title	Dysregulation of the immune response affects the outcome of critical COVID‐19 patients
has PubMed Central identifier	PMC7323247
has PubMed identifier	32543740
schema:publication	J Med Virol
resource representing a document's body	covid:93029948341507916e5ca60e5b0e21858b3578bc#body_text
is schema:about of	named entity 'ICU' named entity 'prognosis' named entity 'significant effect' named entity 'prognosis' named entity 'oxygen saturation' named entity 'mass cytometer' named entity 'DCs' named entity 'prognosis' named entity 'prognosis' named entity 'antibodies' named entity 'COVID-19' named entity 'COVID' named entity 'prognosis' named entity 'ground-glass opacities' named entity 'prognosis' named entity 'CD49d' named entity 'COVID-19' named entity 'critical illness' named entity 'prognosis' named entity 'Tregs' named entity 'blood cells' named entity 'antigen presenting cells' named entity 'antibody' named entity 'prognosis' named entity 'peripheral blood' named entity 'comorbidities' named entity 'CD38' named entity 'functional impairment' named entity 'median age' named entity 'prognosis' named entity 'COVID' named entity 'cisplatin' named entity 'lymphocyte subsets' named entity 'permeabilization' named entity '28 days' named entity 'SARS-CoV-2' named entity 'neutrophil' named entity 'prognosis' named entity 'CD4' named entity 'infection' named entity 'COVID' named entity 'COVID-19' named entity 'COVID-19' named entity 'lungs' named entity 'Beijing' named entity 'Renal function' named entity 'natural killer (NK) cells' named entity 'Fluidigm' named entity 'informed consent' named entity 'National Health Commission of China' named entity 'PBS' named entity 'prognosis' named entity 'prognosis' named entity 'data acquisition' named entity 'antigen' named entity 'antibody' named entity 'COVID' named entity 'DCs' named entity 'Th1' named entity 'prognosis' named entity 'inflammatory response' named entity 'laboratory investigations' named entity 'phenotypes' named entity 'HLA-DR' named entity 'prognosis' named entity 'retrospective cohort study' named entity 'partial pressure of arterial oxygen' named entity 'CXCR3' named entity 'monocyte' named entity 'Fluidigm' named entity 'CD14' named entity 'PBMCs' named entity 'mass cytometry' named entity 'leukocyte' named entity 'infection' named entity 'hypoxemic' named entity 'adaptive immunity'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software